Itraconazole Use in Pregnancy (Antenatal Care)
Itraconazole can be administered during pregnancy for treatment of systemic fungal infections when the expected maternal benefit outweighs fetal risk. [1] Itraconazole should generally be avoided for non–life-threatening indications during pregnancy. [2]
Indication-Dependent Recommendations
Systemic fungal infections are an accepted use case for itraconazole during pregnancy when benefit outweighs risk. [1] Azole antifungals including itraconazole are generally recommended to be avoided during pregnancy for vulvovaginal candidiasis in the IDSA candidiasis guidance. [3]
Medication Selection Algorithm
- Systemic fungal infection requiring systemic azole therapy: itraconazole may be used when benefit outweighs risk (examples: treatment of histoplasmosis or other systemic mycoses when alternatives are not preferred). [1]
- Vulvovaginal candidiasis: local azole therapy (eg, clotrimazole) is favored over systemic azoles in pregnancy recommendations. [3]
- Non–life-threatening fungal conditions (eg, onychomycosis): itraconazole is not recommended during pregnancy. [2]
Initiation Thresholds and Timing Considerations
Itraconazole for systemic fungal infections should be used only when the expected benefit outweighs the potential risk to the fetus. [1] Itraconazole should not be used for onychomycosis during pregnancy. [2]
Practical Prescribing Nuances
For systemic fungal infections, itraconazole dosing often requires therapeutic drug monitoring to ensure adequate exposure during therapy. [4]
Common Pitfalls to Avoid
Itraconazole should not be used for non–life-threatening fungal conditions during pregnancy (example: onychomycosis). [2] Azole selection should not be based only on efficacy in nonpregnant patients for vulvovaginal candidiasis, because pregnancy-specific avoidance of systemic azoles is recommended. [3]
Target Goals of Therapy
For systemic fungal infections, treatment goals in pregnancy are resolution of infection with prevention of maternal disease progression and associated maternal-fetal risk. [1] For vulvovaginal candidiasis, treatment goals are symptom resolution using pregnancy-favored local therapy approaches rather than systemic azoles. [3]